Furthermore, combinations of afatinib with cisplatin (70) or cisplatin treatment followed by afatinib (67) in EGFR wild-type HNSCC cells have led to increased cytotoxicity, suggesting such approaches warrant further investigation in the context of EGFR-amplified OSCC. This evidence concerns the gene EGFR and head and neck squamous cell carcinoma.